AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease

被引:35
作者
Prasad, Kailash [1 ]
Dhar, Indu [1 ]
Zhou, Qifeng [2 ,3 ]
Elmoselhi, Hamdi [2 ,3 ]
Shoker, Muhammad [1 ]
Shoker, Ahmed [2 ,3 ]
机构
[1] Univ Saskatchewan, Dept Physiol, Coll Med, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada
[2] Univ Saskatchewan, Coll Med, Dept Med, Saskatoon, SK, Canada
[3] Univ Saskatchewan, Royal Univ Hosp, Saskatoon, SK, Canada
关键词
Advanced glycation end products (AGEs); Soluble receptors for AGE; sRAGE; esRAGE; cRAGE; AGEs/sRAGE; Inflammation; End-stage renal disease; CIRCULATING SOLUBLE RECEPTOR; CHRONIC KIDNEY-DISEASE; SERUM-LEVELS; CARDIOVASCULAR-DISEASE; PLASMA-LEVELS; PRODUCTS; ATHEROSCLEROSIS; RAGE; ASSOCIATION; AGE;
D O I
10.1007/s11010-016-2829-4
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Interaction of advanced glycation end products (AGEs) with its cell-bound receptor (RAGE) results in cell dysfunction through activation of nuclear factor kappa-B, increase in expression and release of inflammatory cytokines, and generation of oxygen radicals. Circulating soluble receptors, soluble receptor (sRAGE), endogenous secretory receptor (esRAGE) and cleaved receptor (cRGAE) act as decoy for RAGE ligands and thus have cytoprotective effects. Low levels of sRAGE and esRAGE have been proposed as biomarkers for many diseases. However sRAGE and esRAGE levels are elevated in diabetes and chronic renal diseases and still tissue injury occurs. It is possible that increases in levels of AGEs are greater than increases in the levels of soluble receptors in these two diseases. Some new parameters have to be used which could be an universal biomarkers for cell dysfunction. It is hypothesized that increases in serum levels of AGEs are greater than the increases in the soluble receptors, and that the levels of AGEs is correlated with soluble receptors and that the ratios of AGEs/sRAGE, AGEs/esRAGE and AGEs/cRAGE are elevated in patients with end-stage renal disease (ESRD) and would serve as an universal risk marker for ESRD. The study subject comprised of 88 patients with ESRD and 20 healthy controls. AGEs, sRAGE and esRAGE were measured using commercially available enzyme linked immune assay kits. cRAGE was calculated by subtracting esRAGE from sRAGE. The data show that the serum levels of AGEs, sRAGE, cRAGE are elevated and that the elevation of AGEs was greater than those of soluble receptors. The ratios of AGEs/sRAGE, AGEs/esRAGE and AGEs/cRAGE were elevated and the elevation was similar in AGEs/sRAGE and AGEs/cRAGE but greater than AGEs/esRAGE. The sensitivity, specificity, accuracy, and positive and negative predictive value of AGEs/sRAGE and AGEs/cRAGE were 86.36 and 84.88 %, 86.36 and 80.95 %, 0.98 and 0.905, 96.2 and 94.8 %, and 61.29 and 56.67 % respectively. There was a positive correlation of sRAGE with esRAGE and cRAGE, and AGEs with esRAGE; and negative correlation between sRAGE and AGEs/sRAGE, esRAGE and AGES/esRAGE, and cRAGE and AGES/cRAGE. In conclusion, AGEs/sRAGE, AGEs/cRAGE and AGEs/esRAGE may serve as universal risk biomarkers for ESRD and that AGEs/sRAGE and AGEs/cRAGE are better risk biomarkers than AGEs/esRAGE.
引用
收藏
页码:105 / 114
页数:10
相关论文
共 50 条
  • [1] AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease
    Kailash Prasad
    Indu Dhar
    Qifeng Zhou
    Hamdi Elmoselhi
    Muhammad Shoker
    Ahmed Shoker
    Molecular and Cellular Biochemistry, 2016, 423 : 105 - 114
  • [2] Apolipoprotein B is a risk factor for end-stage renal disease
    Kwon, Soie
    Kim, Dong Ki
    Oh, Kook-Hwan
    Joo, Kwon Wook
    Lim, Chun Soo
    Kim, Yon Su
    Han, Seung Seok
    CLINICAL KIDNEY JOURNAL, 2021, 14 (02) : 617 - 623
  • [3] Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease
    Sharma, Sumeet
    Farrington, Ken
    Kozarski, Robert
    Christopoulos, Christos
    Niespialowska-Steuden, Maria
    Moffat, Daniel
    Gorog, Diana A.
    EUROPEAN HEART JOURNAL, 2013, 34 (05) : 354 - +
  • [4] Asymmetric Dimethylarginine: a Novel Cardiovascular Risk Factor in End-stage Renal Disease
    Alsagaff, M. Yusuf
    Thaha, M.
    Aminuddin, M.
    Yogiantoro, R. M.
    Yogiantoro, M.
    Tomino, Y.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2012, 40 (01) : 340 - 349
  • [5] Obesity, metabolic health, and the risk of end-stage renal disease
    Panwar, Bhupesh
    Hanks, Lynae J.
    Tanner, Rikki M.
    Muntner, Paul
    Kramer, Holly
    McClellan, William M.
    Warnock, David G.
    Judd, Suzanne E.
    Gutierrez, Orlando M.
    KIDNEY INTERNATIONAL, 2015, 87 (06) : 1216 - 1222
  • [6] Complement factor H gene polymorphism and risk of cardiovascular disease in end-stage renal disease patients
    Buraczynska, Monika
    Ksiazek, Piotr
    Zukowski, Pawel
    Benedyk-Lorens, Ewa
    Orlowska-Kowalik, Grazyna
    CLINICAL IMMUNOLOGY, 2009, 132 (02) : 285 - 290
  • [7] Lung Congestion as a Risk Factor in End-Stage Renal Disease
    Zoccali, Carmine
    Tripepi, Rocco
    Torino, Claudia
    Bellantoni, Marianna
    Tripepi, Giovanni
    Mallamaci, Francesca
    BLOOD PURIFICATION, 2013, 36 (3-4) : 184 - 191
  • [8] Oxidative Balance Score and the Risk of End-Stage Renal Disease and Cardiovascular Disease
    Ilori, Titilayo O.
    Wang, Xiao
    Huang, Morong
    Gutierrez, Orlando M.
    Narayan, K. M. Venkat
    Goodman, Michael
    McClellan, William
    Plantinga, Laura
    Ojo, Akinlolu O.
    AMERICAN JOURNAL OF NEPHROLOGY, 2017, 45 (04) : 338 - 345
  • [9] Homelessness and Risk of End-stage Renal Disease
    Maziarz, Marlena
    Chertow, Glenn M.
    Himmeffarb, Jonathan
    Hall, Yoshio N.
    JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED, 2014, 25 (03) : 1231 - 1244
  • [10] Atopic Dermatitis and the Risk of Infection in End-Stage Renal Disease
    Momin, Rushan I.
    Baer, Stephanie L.
    Waller, Jennifer L.
    Young, Lufei
    Tran, Sarah
    Taskar, Varsha
    Bollag, Wendy B.
    MEDICINA-LITHUANIA, 2023, 59 (12):